341170.Kn
341170.KN operates in the Pharmaceuticals industry, focusing on Pharmaceuticals & Medical Research, and generates revenue primarily through the development and sale of pharmaceutical products.
Business. 341170.KN operates in the Pharmaceuticals industry, focusing on Pharmaceuticals & Medical Research, and generates revenue primarily through the development and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
341170.KN operates in the Pharmaceuticals industry, focusing on Pharmaceuticals & Medical Research, and generates revenue primarily through the development and sale of pharmaceutical products.
The company's capital structure is highly leveraged, with total liabilities of KRW 421.5 billion and total equity of -KRW 354.0 billion, resulting in a debt-to-equity ratio of -0.9. The company has negative net cash, with cash and equivalents of KRW 212.5 billion and long-term debt of KRW 316.9 billion, indicating a liquidity risk. The current ratio of 0.08 further highlights the company's weak short-term liquidity position.
Profitability metrics are severely negative, with a return on assets of -2.42 and a return on equity of 0.461. These figures indicate that the company is not generating returns that cover its cost of capital and is operating at a loss. The operating income and net income are both negative, at -KRW 1.64 billion and -KRW 1.63 billion, respectively.
The company's revenue is reported as zero, which suggests either a reporting error or a complete absence of revenue-generating activities. There is no information provided on segments or geographic exposure, making it difficult to assess revenue concentration or diversification.
The company's growth trajectory is unclear due to the lack of historical revenue data and the absence of forward-looking guidance. The negative operating and net income figures indicate a lack of profitability, which could hinder future growth. The risk assessment highlights a medium liquidity risk and a low dilution risk, but the key flag of negative net cash after subtracting total debt is a significant concern.
Recent events and filings are not detailed in the provided data, so there is no information on recent developments that could impact the company's financial position or strategic direction.
- The company has a highly leveraged capital structure with a debt-to-equity ratio of -0.9.
- Profitability is severely negative, with a return on assets of -2.42 and a return on equity of 0.461.
- The company has negative net cash, indicating a liquidity risk.
- Revenue is reported as zero, suggesting either a reporting error or a lack of revenue-generating activities.
- The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 341170.KN Market data — financials · 2026-05-26